FDA Approves First Adjuvant Immunotherapy for a Common Form of Stage III Colon Cancer: What the NCI-Funded ATOMIC Trial Found

On October 9, 2026, the FDA approved Genentech/Roche's checkpoint inhibitor Tecentriq (atezolizumab) — paired with the chemotherapy drugs fluoropyrimidine and oxaliplatin — as an adjuvant (after-surgery) treatment for a specific subtype of stage III colon cancer. The approval is built on results from ATOMIC, a 712-patient, NCI-funded phase 3 trial that found adding immunotherapy to standard chemotherapy nearly halved the risk of cancer recurrence or death in patients whose tumors carry a biological feature called mismatch repair deficiency (dMMR). This article explains what was approved, what the trial actually showed, who it applies to, and what still isn't known.

A New Option After Surgery, Not Just for Advanced Disease

Most of the immunotherapy headlines in colon cancer over the past decade have focused on metastatic, late-stage disease. This approval is different — and arguably more consequential for long-term survival. It targets patients who have just had surgery to remove a stage III colon tumor (meaning the cancer has reached nearby lymph nodes but hasn't spread to distant organs) and are now in the "adjuvant" window, where additional treatment is given specifically to kill off microscopic cancer cells that surgery and scans can't detect, in hopes of preventing the cancer from coming back. Genentech describes this as Tecentriq's twelfth approved US indication overall, and the first approved adjuvant immunotherapy regimen specifically for this colon cancer setting.

The catch — and it's an important one — is that this approval doesn't apply to all stage III colon cancer. It's restricted to tumors with deficient mismatch repair (dMMR), also sometimes identified as microsatellite instability-high (MSI-H), a molecular signature that makes tumors unusually visible to the immune system. According to Roche, roughly 15% of colon cancers overall carry this feature. Nearly 25% of colon cancers are diagnosed at stage III, and without additional treatment, close to 30% of stage III patients see their cancer return within five years. So this approval carves out a meaningful, biomarker-defined slice of colon cancer patients for whom a genuinely new, more effective option now exists.

The Data Behind the Approval: What ATOMIC Actually Found

The approval rests on ATOMIC (also known as Alliance A021502, ClinicalTrials.gov NCT02912559), a randomized, open-label phase 3 trial run through the Alliance for Clinical Trials in Oncology — part of the National Cancer Institute's National Clinical Trials Network — with Genentech supporting the study under a cooperative research agreement. This is worth underlining for patients weighing the evidence: the trial wasn't an industry-run registration study designed primarily to win approval. It was a publicly funded, NIH/NCI-sponsored academic trial, led by Dr. Frank Sinicrope of the Mayo Clinic, that happened to produce a result strong enough to support one.

Between 2017 and 2023, 712 patients with surgically resected, dMMR stage III colon cancer were randomly assigned 1:1 to either standard mFOLFOX6 chemotherapy alone, or the same chemotherapy plus six months of atezolizumab followed by six additional months of atezolizumab alone. The primary endpoint was disease-free survival (DFS) — essentially, how long patients lived without their cancer coming back.

The results, first presented at ASCO in 2025 and now the basis for FDA approval, are genuinely striking for an adjuvant oncology trial: at three years (36 months), 86% of patients who received atezolizumab plus chemotherapy were disease-free, compared with 76% of those who received chemotherapy alone — the sponsor describes this as roughly a 50% reduction in the risk of recurrence or death. The trial crossed its pre-specified efficacy boundary at a planned interim analysis, a sign the benefit was large and consistent enough that investigators didn't need to wait for the full planned follow-up to see it. Subgroup analyses showed the benefit held up fairly consistently across age, sex, tumor location, and other baseline factors, though some of those subgroup confidence intervals were wide, as is typical when a large trial is sliced into smaller patient groups.

What's Still Unknown or Unresolved

A few caveats genuinely matter here, and they shouldn't be glossed over. First, ATOMIC was open-label — patients and treating physicians knew who was getting the extra immunotherapy, which can introduce some bias into how recurrences are monitored or reported, even with objective scan-based endpoints. Second, the approval and the headline data are built on disease-free survival, a well-accepted surrogate endpoint in colon cancer, but mature overall survival data — whether patients actually live longer, not just longer without detectable recurrence — has not yet been reported publicly. That's not unusual for an adjuvant trial still accumulating follow-up, but it means the long-term survival payoff, while expected to track DFS, isn't yet confirmed. Third, on safety, Genentech and investigators describe the combination's side-effect profile as "consistent with" the known profiles of atezolizumab and chemotherapy individually, with one specific signal reported in trial coverage: a manageable increase in non-febrile (non-fever) low white blood cell counts (neutropenia) compared with chemotherapy alone. Finally, this is not a treatment for colon cancer broadly — it requires dMMR/MSI-H biomarker testing, something not every patient's tumor will show.

What Comes Next for Patients

For the roughly 15% of colon cancer patients whose stage III tumors test dMMR-positive, this approval gives oncologists a new, evidence-backed, NCI-validated option to discuss immediately after surgery, rather than waiting for the cancer to recur and treating it in the metastatic setting, where outcomes are harder to reverse. Patients and caregivers should ask specifically whether mismatch repair or MSI testing has been done on their tumor tissue, since that result determines eligibility for this regimen. As with any new adjuvant indication, the next few years of real-world use and continued trial follow-up — particularly on overall survival — will clarify how durable this benefit is outside the trial setting.

Bottom Line

The FDA's October 2026 approval of atezolizumab for adjuvant treatment of dMMR stage III colon cancer is a well-earned win built on a publicly funded, rigorously conducted phase 3 trial that substantially reduced recurrence risk for a defined subset of patients. It is not a cure-all for colon cancer, it applies only to the dMMR/MSI-H biomarker-positive minority of cases, and mature overall survival data are still pending — but for the right patients, it represents a real, immediately actionable advance in care after surgery, not just another incremental trial readout.